Optimizing the Treatment Schedule of Radiotherapy Combined With Anti-PD-1/PD-L1 Immunotherapy in Metastatic Cancers

Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein-1 (PD-1), and programmed cell death ligand-1 (PD-L1) have been approved for a variety of malignant tumors and are widely used to treat patients with metastatic disease. However, the efficacy of PD-1 inhibitors is limited due...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Yuehong, Ma, Yifu, Zhao, Xiangrong, Pan, Jie, Xu, Zhi, Zhang, Liyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042160/
https://www.ncbi.nlm.nih.gov/pubmed/33859942
http://dx.doi.org/10.3389/fonc.2021.638873

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042160/
https://www.ncbi.nlm.nih.gov/pubmed/33859942
http://dx.doi.org/10.3389/fonc.2021.638873

Ejemplares similares